A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Overview

About this study

The purpose of this study is to compare the effectiveness and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Female patients ≥ 18 years of age.
  • Patients must have a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.
  • Patients must have platinum-resistant disease:
    • Patients who have only had 1 line of platinum based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between > 3 months and ≤ 6 months after the date last dose of platinum;
    • Patients who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum.
    • Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.
    • Note: Patients who are platinum-refractory during front-line treatment are excluded (see exclusion criteria).
  • Patients must have progressed radiographically on or after their most recent line of therapy.
  • Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity.
  • Patient’s tumor must be positive for FRα expression as defined by the Ventana FOLR1 (FOLR-2.1) CDx assay.
  • Patients must have at least one lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the Investigator).
  • Patients must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment:
    • Adjuvant ± neoadjuvant considered one line of therapy
    • Maintenance therapy (e.g., bevacizumab, PARP inhibitors) will be considered as part of the preceding line of therapy (i.e., not counted independently);
    • Therapy changed due to toxicity in the absence of progression will be considered as part of the same line (i.e., not counted independently);
    • Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance.
  • Patient must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  • Time from prior therapy:
    • Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter);
    • Focal radiation completed at least 2 weeks prior to first dose of study drug.
  • Patients must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities.
  • Major surgery must be completed at least 4 weeks prior to first dose and have recovered or stabilized from the side effects of prior surgery
  • Patients must have adequate hematologic, liver, and kidney functions defined as:
    • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9 /L (1,500/μL) without G-CSF in the prior 10 days or long-acting WBC growth factors in the prior 20 days;
    • Platelet count ≥ 100 x 10^9 /L (100,000/μL) without platelet transfusion in the prior 10 days;
    • Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days;
    • Serum creatinine ≤ 1.5 x upper limit of normal (ULN);
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN f. Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN);
    • Serum albumin ≥ 2 g/dL.
  • Patients or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements.
  • Women of childbearing potential (WCBP) must agree to use highly effective contraceptive method(s) in while on study drug and for at least 3 months after the last dose of MIRV or at least 6 months after the last dose of Pac, PLD, or Topo.
  • WCBP must have a negative pregnancy test within 4 days prior to the first dose of study drug.

Exclusion Criteria:

  • Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade or borderline ovarian tumor.
  • Patients with primary platinum-refractory disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy.
  • Patients with prior wide-field radiotherapy (RT) affecting at least 20% of the bone marrow.
  • Patients with > Grade 1 peripheral neuropathy per Common Terminology Criteria for Adverse Events (CTCAE).
  • Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision.
  • Patients with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:
    • Active hepatitis B or C infection (whether or not on active antiviral therapy);
    • HIV infection;
    • Active cytomegalovirus infection;
    • Any other concurrent infectious disease requiring IV antibiotics within 2 weeks before starting study drug.
    • Note: Testing at screening is not required for the above infections unless clinically indicated.
  • Patients with history of multiple sclerosis or other demyelinating disease and/or LambertEaton syndrome (paraneoplastic syndrome).
  • Patients with clinically significant cardiac disease including, but not limited to, any one of the following:
    • Myocardial infarction ≤ 6 months prior to first dose;
    • Unstable angina pectoris;
    • Uncontrolled congestive heart failure (New York Heart Association > class II);
    • Uncontrolled ≥ Grade 3 hypertension (per CTCAE);
    • Uncontrolled cardiac arrhythmias.
  • Patients assigned to PLD stratum only:
    • Left ventricular ejection fraction (LVEF) below the institutional limit of normal as measured by echocardiography (ECHO) or multigated acquisition (MUGA) scan.
  • Patients with a history of hemorrhagic or ischemic stroke within six months prior to randomization.
  • Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C).
  • Patients with a previous clinical diagnosis of non-infectious interstitial lung disease (ILD), including noninfectious pneumonitis.
  • Patients with required use of folate-containing supplements (e.g., folate deficiency).
  • Patients with prior hypersensitivity to monoclonal antibodies.
  • Women who are pregnant or lactating.
  • Patients with prior treatment with MIRV or other FRα-targeting agents.
  • Patients with untreated or symptomatic central nervous system (CNS) metastases.
  • Patients with a history of other malignancy within 3 years prior to randomization.
    • Note: does not include tumors with a negligible risk for metastasis or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast).
  • Prior known hypersensitivity reactions to study drugs and/or any of their excipients.
  • People who are detained through a court or administrative decision, receiving psychiatric care against their will, adults who are the subject of a legal protection order (under tutorship/curatorship), people who are unable to express their consent, and people who are subject to a legal guardianship order.
  • Simultaneous participation in another research study, in countries or localities where this is the health authority guidance.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Saravut Weroha, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Gerardo Colon-Otero, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Kristina Butler, M.D., M.S.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20490425

Mayo Clinic Footer